ARCHIVES

Tivozanib Does Not Improve OS Compared to Sorafenib

This article is from The Cancer Letter archive.

Vol. 36 No. 2 | February 22, 2013

Download PDF Visit The Full Archive

Related Articles

ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay

July 17, 2009

Raymond Weiss Reviews Confidential Report on I-ELCAP

April 29, 2011

FDA Proposes New User Fees for Generics and Biosimilar Products

January 20, 2012

Trombold Tells How Scripps Raises Money for Cancer Center, Gets Independent From “Whiny Administrator”

April 5, 1985

CMS Proposes To End Automatic Coverage Of Clinical Trials For Medicare Patients.

October 12, 2007

Abstracts From AACR Annual Meeting

June 4, 1976